Initial Announced Date: 2023-08-28 (August 28, 2025), Updated in 2023-12-18 (December 18, 2023)
Asset: Three oncology discovery programs targeting RAS pathway-driven cancers
Licensor: GenFleet Therapeutics (China)
Licensee (Buyer): Verastem Oncology (US)
.
Lead Program: GFH375/VS-7375 (Announced in December 18, 2023)
Asset Modality: Small molecule, orally
Asset Target: KRAS G12D (ON/OFF) inhibitor
Potential Indication: Cancer
Current Stage: PreClinical
.
Scope of Authority:
The IND filing and initial Phase 1 studies will be led and funded by GenFleet in China.
The collaboration provides Verastem Oncology with an exclusive option to obtain a license to each of the three compounds in the collaboration after successful completion of pre-determined milestones in a Phase 1 trial.
The licenses would give Verastem Oncology development and commercialization rights outside of China while GenFleet would retain development and commercialization rights inside of China.
.
Payment Detail:
The terms of the agreement include combined upfront, research support and option payments to GenFleet of $11.5 million for the first program,
with potential total deal size across all three programs up to $625.5 million excluding royalties if Verastem Oncology exercises its in-license options.
.
Link:
